Drug Approval | February 10, 2022
USFDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences
Adds five years of market exclusivity on approval
Adds five years of market exclusivity on approval
Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
The CAS SciFinder Discovery Platform expansion unlocks human-indexed insights from journals and patents in over 50 languages dating back to 1957 and 70 million biosequences curated by CAS scientists
UCB plans to submit regulatory applications in Q3 2022
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
